Rigel Pharmaceuticals (RIGL) Capital Leases (2010 - 2016)

Rigel Pharmaceuticals' Capital Leases history runs 4 years deep, the most recent figure standing at $238000.0 for Q4 2016.

• On a quarterly basis, Capital Leases fell 93.12% year-over-year to $238000.0 in Q4 2016; TTM through Dec 2016 was $238000.0, a 93.12% decrease from a year earlier, with the FY2016 full-year figure at $238000.0, down 93.12% from the prior year.
• Capital Leases declined to $238000.0 in Q4 2016 per RIGL's latest filing, from $1.1 million in the prior quarter.
• Across five years, Capital Leases topped out at $6.5 million in Q4 2014 and bottomed at $238000.0 in Q4 2016.
• The 3-year median for Capital Leases is $3.5 million (2015), against an average of $3.4 million.
• Across the five-year window, Capital Leases sank 46.49% in 2015 and sank 93.12% in 2016, its largest moves.
• Year by year, Capital Leases stood at $6.5 million in 2014, then sank by 46.49% to $3.5 million in 2015, then plunged by 93.12% to $238000.0 in 2016.
• Per Business Quant, the three latest RIGL Capital Leases figures stand at $238000.0 (Q4 2016), $1.1 million (Q3 2016), and $1.9 million (Q2 2016).